Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Stellate Ganglion Block With Dexmedetomidine or Ketamine for Neurostorm After Traumatic Brain Injury
NCT06354673Completed
- Sponsor
- Zagazig University
- Start
- Apr 2024
- Primary completion
- Sep 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial of dexmedetomidine and ketamine in Paroxysmal Sympathetic Hyperactivity (PSH) (2 arms), sponsored by Zagazig University. Primary endpoints: Time of remission of neurostorm symptoms at 6 months and Glasgow Coma Scale score at 6 months. Started Apr 2024; status: completed.
02
Drugs
dexmedetomidineketamine
03
Conditions
Paroxysmal Sympathetic Hyperactivity (PSH)
Beyond the preview
Go deeper on NCT06354673.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06354673.